anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a nitrofurazone and borax spray. The nitrofurazone and borax spray contains nitrofurazone of 0.01-0.5 g/L, borax of 0.3-150 g/L and glycerinum aqueous solution of 50-900 g/L. The invention further provides a preparing method of the nitrofurazone and borax spray. The method comprises the steps of 1, dissolving borax in glycerinum to prepare solution 1; 2, dissolving nitrofurazone in a proper amount of hot water which is 80-100 DEG C to prepare solution 2; 3, adding the solution 2 to the solution 1, and conducting uniform mixing to obtain the nitrofurazone and borax spray. The nitrofurazone and borax spray is suitable for disinfection and antisepsis of skin wound, stomatitis, gingivitis, pharyngitis and amygdalitis, has a remarkable treatment effect on various skin tinea, and can also treat otitis media suppurative and acute and chronic rhinitis through ear dripping and nasal dripping. The product and the preparing process are simple, production cost is low, antibacterial effect is good, stability is high, and safety is high. A spray form is adopted, and the nitrofurazone and borax spray has the advantages of being capable of becoming effective quickly, convenient to carry and use and wide in application range.
Along with birth weight and parental body size, infant feeding is recognized as one of the most influential biological and environmental factors that affect weight gain during infancy. Parental feeding practices have a strong impact on children's food availability, eating behaviors, and weight. The Institute of Medicine's(IOM) recent report (2011) on early childhood obesity prevention policies recommends five approaches to preventing obesity: assess, monitor, and track growth from birth to age 5; increase physical activity and decrease sedentary behavior in young children; support breastfeeding and be responsive to children's feeding cues; limit screen time; and promote age-appropriate sleep for young children. Based on the previous work by this research team, and in collaboration with a major urban health department, we propose to test an intervention that incorporates all the IOM's recommendations to prevent the development of obesity in at-risk infants. The intervention will be guided by health professionals and delivered through home visits by community health workers (CHWs), supervised by public health nurses (PHN), to Mexican American women and children who are clients of the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) Program in Houston, TX. The intervention will occur for 2 years with 1 year of follow-up, for a total of 3 years of measures.
Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the ED visit will serve as our intervention group. The participants will be assigned an Ambassador throughout the child's ED visit and will complete a patient satisfaction survey afterwards. The investigators hold to enroll 120 controls.
In group 2, the patient benefits from a nurse consultation. Non-medicinal techniques are not offered. During the infusion test, the nurse will be positioned at the patient's head allowing proximity but without oral or physical intervention.
Patients are subgroup of previously published study (JACC Cardiovascular Intervention 2020;13:1155-67), which evaluated invasive physiologic indices from culprit and non-culprit vessels of acute myocardial infarction patients. From the study cohort, 31 STEMI patients who underwent IMR measurement in culprit vessel after successful revascularization will be analyzed. In these patients, diagnostic accuracy of angiography-derived IMR will be compared with invasive IMR.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to preparing drugs from plant raw. Agent and biologically active addition have the fat-free spotted milk thistle (Silybum) fruits and microalga spirulina biomass taken in the definite ratio. Agent ensures to achieve the increase of expressed hepatoprotective effect (by 20-30% as compared with the nearest analog) due to optimal combination of hepatoprotective, immunocorrecting and antioxidative properties of substances and their synergistic effect. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 2 cl, 3 ex
The present invention is related to sulfonamide derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of INK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, ? is 0 or S, preferably 0; R1 is hydrogen or a Ñ1-Ñ6-alkyl group, or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Arl; n is an integer from 0 to 5, preferably between l-3 and most preferred l; ? within formula (I) is an unsubstituted or a substituted 4-l2-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide. (I).
<P>PROBLEM TO BE SOLVED: To provide a general solution for transmitting multilingual subtitles with a video program in the MPEG2 environment, in particular, in a method of simultaneously transmitting video signal and encoded data representing graphic videos.  <P>SOLUTION: The graphic videos are rectangular regions within the active video area. They are transmitted in a form of bitmaps. The present invention not only allows character fonts or the size to be displayed, but also the definition of e.g. a program provider's logo. The encoded data include a time stamp to specify the time at which a subtitle is to be displayed. This allows multilingual subtitles to be transmitted, in advance and to be displayed accurately, in synchronism with the video signal.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Study is a multicenter, randomized, double-blind, parallel, placebo-controlled, 20-week trial with 4 study periods. Participants who screen successfully (Study Period I) will be randomized in a 1:1 fashion to duloxetine 60 mg QD or placebo. Starting with Study Period II, participants will be treated in a double-blind manner for 6 weeks. Participants who complete the 6-week, double-blind period will have the opportunity to participate in a 12-week, open-label, flexible-dose portion of the study (Study Period III). Study Period IV is a taper phase designed to reduce the occurrence of discontinuation adverse events. Participants may enter Study Period IV at any time after Visit 3.
The resistance of glioblastomas (GBM) to standard therapies poses a clinical challenge with limited survival despite interventions. The tumor microenvironment (TME) orchestrates GBM progression, comprising stromal and immune cells and is characterized by extensive hypoxic regions. Hypoxia activates the hypoxia-inducible factor 1 alpha (HIF-1α) pathway, interacting with the Hippo pathway (YAP/TAZ) in crucial cellular processes. We discuss here the related signaling crosstalk between YAP/TAZ and regions of hypoxia in the TME with particular attention on the MST1/2 and LATS1/2-regulated YAP/TAZ activation, impacting cell proliferation, invasion, and stemness. Moreover, the hypoxia-YAP/TAZ axis influence on angiogenesis, stem cells, and metabolic regulators is defined. By reviewing extracellular matrix alterations activation of YAP/TAZ, modulation of signaling pathways we also discuss the significance of spatial constraints and epigenetic modifications contribution to GBM progression, with potential therapeutic targets in YAP/TAZ-mediated gene regulation. Comprehensive understanding of the hypoxia-Hippo pathway-TME interplay offers insights for novel therapeutic strategies, aiming to provide new directions for treatment.
PROBLEM TO BE SOLVED: To attain a sterilized connection in a cell processing system having a rotary processing vessel and a material feed port by receiving a pressurized gas or fluid in at least one annular space of a plurality of annular rotating seals. SOLUTION: A rotary seal is provided with upper and lower sealing members 610, 620 to form a first and second seals 700, 702 and the upper boundary of an annular space 710 between them. The annular space 710 is communicatable with the external environment and also gas-communicates through a passage 616, and the passage 616 is formed of either one of the seal members 610, 620. A first port 632, which ends in a plug 690 across axial opening, functions as the inlet into a cell processing vessel, and a fluid port 636 fluid-communicates with the annular space 638 and is used for the movement of a processing material to the processing vessel. A gas port 634 communicates with the annular space 710 and functions as the inlet for supplying sterilized air and pressurizing the annular space 710. A spring 640 is formed of a cylindrical elastic member to generate an enhanced seal.
<P>PROBLEM TO BE SOLVED: To provide an agent for the hair effective for growing the hair.  <P>SOLUTION: A mushroom extract liquid containing ergothioneine was applied to the top of the human head at about 4-8 cm<SP>3</SP>per day. As a result, the hair as shown in Fig.(A) has become as shown in Fig.(B) after about two months, enabling the effect of hair growth to be confirmed throughout top of the head. It is believed that, as a result of ergothioneine's action on the hair root cells or hair matrix cells of the hair, these cells are activated, resulting in growing the hair.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Glioma cells overexpress different peptide receptors that are useful for research, diagnosis, management, and treatment of the disease. Oncogenic peptides favor the proliferation, migration, and invasion of glioma cells, as well as angiogenesis, whereas anticancer peptides exert antiproliferative, antimigration, and anti-angiogenic effects against gliomas. Other peptides exert a dual effect on gliomas, that is, both proliferative and antiproliferative actions. Peptidergic systems are therapeutic targets, as peptide receptor antagonists/peptides or peptide receptor agonists can be administered to treat gliomas. Other anticancer strategies exerting beneficial effects against gliomas are discussed herein, and future research lines to be developed for gliomas are also suggested. Despite the large amount of data supporting the involvement of peptides in glioma progression, no anticancer drugs targeting peptidergic systems are currently available in clinical practice to treat gliomas.
Hand-and-foot syndrome (palmar-plantar erythrodysesthesia or chemotherapy-induced acral erythema) is a cutaneous toxicity. Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving XELODA monotherapy in the metastatic setting. Grade 1 is characterized by any of the following: numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt normal activities. Grade 2 hand-and-foot syndrome is defined as painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient's activities of daily living. Grade 3 hand-and-foot syndrome is defined as moist desquamation, ulceration, blistering or severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. If grade 2 or 3 hand-and-foot syndrome occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-and-foot syndrome, subsequent doses of XELODA should be decreased (see DOSAGE AND ADMINISTRATION).
* Mild Hepatic Impairment (Child-Pugh Class A): No dose modification is recommended. Liver function tests should be closely monitored.
  * Moderate Hepatic Impairment (Child-Pugh Class B): Treatment is not recommended. Use of TRIKAFTA in patients with moderate hepatic impairment should only be considered when there is a clear medical need, and the benefit exceeds the risk. If used in patients with moderate hepatic impairment, TRIKAFTA should be used at a reduced dose [see Dosage and Administration (2.2)]. Liver function tests should be closely monitored.  
In a clinical study of 11 subjects with moderate hepatic impairment, one subject developed total and direct bilirubin elevations >2 × ULN, and a second subject developed direct bilirubin elevation >4.5 × ULN [see Clinical Pharmacology (12.3)].
  * Severe Hepatic Impairment (Child-Pugh Class C): Should not be used. TRIKAFTA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), but the exposure is expected to be higher than in patients with moderate hepatic impairment [see Dosage and Administration (2.2), Warnings and Precautions (5.1), Adverse Reactions (6) and Clinical Pharmacology (12.3)].
An augmented wellness environment is generated at a media processing device, where the augmented wellness environment includes a virtual object. The content of the augmented wellness environment is determined by the activities (e.g., participation in wellness activities) of the user and one or more additional users (e.g., users at a similar location to the user). The augmented wellness environment may be modified based on interactions between users. and the augmented wellness environment may also be modified based on user activity data, such as biometric data (e.g., heart rate, breathing rate, etc.) of one or more users experiencing the augmented wellness environment. Using the user activity data, the system may determine a user's present mental state. The system can modify the augmented wellness environment to alter the user's present mental state to a target mental state.
BACKGROUND: Understanding the causes of hypertension is important in order to prevent the disease. Gut microbiota (GM) seems to play an important role, but the detailed physiology remains elusive, with alpha diversity being the most studied indicator.
OBJECTIVES: This review aimed to systematically synthesize data on gut microbiota (alpha diversity) and hypertension.
METHODS: Databases, including MEDLINE/PubMed, Scopus, and EMBASE, and citations were systematically queried. We retrieved articles reporting the association between gut microbiota and hypertension. A valid critical appraisal tool was also used to investigate the quality of the included studies.
RESULTS: Eighteen eligible studies met our inclusion criteria. In this report, we focused on the following indices of alpha diversity: Shannon, Chao1, Simpson, and Abundance-based Coverage Estimator (ACE) indices. Several studies observed a significantly lower Shannon index in hypertensive patients compared to the healthy control group. Nevertheless, no statistically significant difference was found for the Chao1, Simpson, and ACE indices between hypertensive patients and controls. A higher Firmicutes-to-Bacteroidetes ratio (F/B ratio) was consistently observed in hypertensive patients compared to healthy controls, indicating potential dysbiosis in the gut microbiota.
CONCLUSIONS: Our systematic review indicates that hypertensive patients may exhibit an imbalance in gut microbiota, evidenced by decreased alpha diversity and an elevated F/B ratio. However, the absence of statistically significant differences in secondary diversity indices (Chao1, Simpson, and ACE) highlights the need for further research. Well-designed, large-scale studies are necessary to clarify these associations and explore the role of gut microbiota in hypertension development.
Interactions between extracellular matrix (ECM) proteins and β1 integrins play an essential role maintaining vascular integrity in the brain, particularly under vascular remodeling conditions. As blood vessels in the spinal cord are reported to have distinct properties from those in the brain, here we examined the impact of β1 integrin inhibition on spinal cord vascular integrity, both under normoxic conditions, when blood vessels are stable, and during exposure to chronic mild hypoxia (CMH), when extensive vascular remodeling occurs. We found that a function-blocking β1 integrin antibody triggered a small degree of vascular disruption in the spinal cord under normoxic conditions, but under hypoxic conditions, it greatly enhanced (20-fold) vascular disruption, preferentially in spinal cord white matter (WM). This resulted in elevated microglial activation as well as marked loss of myelin integrity and reduced density of oligodendroglial cells. To understand why vascular breakdown is localized to WM, we compared expression levels of major BBB components of WM and grey matter (GM) blood vessels, but this revealed no obvious differences. Interestingly however, hypoxyprobe staining demonstrated that the most severe levels of spinal cord hypoxia induced by CMH occurred in the WM. Analysis of brain tissue revealed a similar preferential vulnerability of WM tracts to show vascular disruption under these conditions. Taken together, these findings demonstrate an essential role for β1 integrins in maintaining vascular integrity in the spinal cord, and unexpectedly, reveal a novel and fundamental difference between WM and GM blood vessels in their dependence on β1 integrin function during hypoxic exposure. Our data support the concept that the preferential WM vulnerability described may be less a result of intrinsic differences in vascular barrier properties between WM and GM, and more a consequence of differences in vascular density and architecture.
Staining compositions comprise a di- or triamino triphenylmethane dye having an alkyl substituent of 8-12 carbon atoms on one of the benzene rings para to the methane carbon atom, and a solvent. Fillers for wood, film-forming substances, fluorescent dyes, or colourless optical brighteners may also be incorporated.  The triphenylmethane dyes may be made by the usual methods using appropriately alkylated starting materials. Solvents specified are diethylene glycol monoethyl or monobutyl ether, or the monomethyl or monoethyl ether of ethylene glycol, triethanolamine, glycerin, glycerol ethers, butyl lactate, triethylamine, chlorinated diphenyls, ethylene glycol and similar alkylene glycols, sulphur treated oils, and sulphonated oils such as ichthyol, alcohols, e.g. methanol, or ethanol, toluol, acetone, ethyl acetate, petroleum distillates, benzol, solvent naphtha, xylols, ethyl benzene.  Film-forming ingredients specified are nitrocellulose and nitrodextran.  Fillers specified are dextran, silex, corn flour, wood flour, starch flour, and the stain-filler compositions may contain drying oils, e.g. Chinawood oil, or resins such as damar, rosin ester gum, or phthalic-glyceride resin.  Pigments may also be incorporated. Triphenylmethane dyes specified include alkylated Malachite Green or Rosaniline and derivatives thereof.  Fluorescent dyes specified are various phenolphthalein and phenol succein derivatives, di-(p-dimethylaminophenyl) ketone imine hydrochloride, 2,3-diphenyl N-phenyl quinoxalonium sulphate and p,p1 - di - [p111 - (p11 - aminobenzoylamino)-aminobenzoylamino] - stilbene - o,o1 - disodium sulphonate) blue.  Colourless optical brighteners specified include coumarin, stilbene, aminonaphthalene, and benzimidazol derivatives.
Secondary brain injury (SBI) is a noticeable contributor to the high mortality and morbidity rates associated with intracerebral hemorrhage (ICH), and effective treatment options remain limited. Cystatin C (CysC) emerges as a novel candidate for SBI intervention. The therapeutic effects and underlying mechanisms of CysC in mitigating SBI following ICH were explored in the current research. An in vivo ICH rat model was established by injecting autologous blood into the right caudate nucleus. Western blotting (WB) was utilized to assess the levels of CysC, cathepsin B (CTSB), and the NLRP3 inflammasome. Subsequently, the ICH rat model was treated with exogenous CysC supplementation or CysC knockdown plasmids. Various parameters, including Evans blue (EB) extravasation, brain water content, and neurological function in rats, were examined. RT-qPCR and WB were employed to determine the expression levels of CTSB and the NLRP3 inflammasome. The co-expression of CTSB, CysC, and NLRP3 inflammasome with GFAP, NeuN, and Iba1 was assessed through double-labeled immunofluorescence. The interaction between CysC and CTSB was investigated using double-labeled immunofluorescence and co-immunoprecipitation. The findings revealed an elevation of CysC expression level, particularly at 24 h after ICH. Exogenous CysC supplementation alleviated severe brain edema, neurological deficit scores, and EB extravasation induced by ICH. Conversely, CysC knockdown produced opposite effects. The expression levels of CTSB and the NLRP3 inflammasome were significantly risen following ICH, and exogenous CysC supplement attenuated their expression levels. Double-labeled immunofluorescence illustrated that CysC, CTSB, and the NLRP3 inflammasome were predominantly expressed in microglial cells, and the interaction between CysC and CTSB was evidenced. CysC exhibited potential in ameliorating SBI following ICH via effectively suppressing the activation of the NLRP3 inflammasome mediated by CTSB specifically in microglial cells. These findings underscore the prospective therapeutic efficacy of CysC in the treatment of ICH-induced complications.
OBJECTIVES: In India, frailty has been predominantly studied as a physiological aspect, overlooking the subjective perceptions of community-dwelling older adults, which holds global significance. This study aims to explore frailty perceptions among community-dwelling older adults, comparing those enrolled in a geriatric welfare program facility to those not-enrolled.
METHODS: A cross-sectional design with a qualitative descriptive framework was employed, using focus group methodology. The study took place in rural West Bengal, located in eastern India, with a sample of 27 participants aged 60-87 years. Data collection occurred between October 2018 and January 2020, conducted through a face-to-face, semistructured discussion guide. Thematic analysis was performed to ensure data saturation and reliability.
RESULTS: Three key themes emerged from the analysis: (a) Perceptions of frailty were associated with aging, functional dependence, and psychosocial health, (b) Exposure to a scientific definition led to an ideological dilemma influenced by personal experiences, (c) Walking speed and grip strength were prominent components of frailty. The findings revealed that there was no difference in perception between program-enrolled and nonenrolled older adults, likely due to the concept of frailty being new to all participants. However, it was noteworthy that participants enrolled in the welfare program exhibited a resilient mindset toward the definition and demonstrated a proactive interest in preserving their overall health.
DISCUSSION: This novel study underscores the necessity of enhancing community awareness and integrating frailty management into the Indian health care system, which is yet to be fully integrated, aiming to promote the well-being of older adults.